The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
High level monocyte chemoattractant protein-1 expression in transgenic mice increases their susceptibility to intracellular pathogens
Abstract
We have constructed transgenic mice in which the mouse mammary tumor virus long terminal repeat controls the expression of murine monocyte chemoattractant protein-1 (MCP-1). Several independently derived lines of transgenic mice constitutively expressed MCP-1 protein in a variety of organs. Protein extracts from these organs had substantial in vitro monocyte chemoattractant activity that was neutralized by an anti-MCP-1 Ab, indicating that transgenic MCP-1 protein is biologically active. However, no transgenic mouse at any age displayed monocyte infiltrates in MCP-1-expressing organs. Two transgenic lines had circulating MCP-1 levels of 13 to 26 ng/ml, which is a concentration sufficient to induce maximal monocyte chemotaxis in vitro. These transgenic lines showed a 1 to 1.5 log greater sensitivity to infection with Listeria monocytogenes and Mycobacterium tuberculosis. A third transgenic line had lower serum levels of MCP-1 and was resistant to L. monocytogenes. The results suggest that this transgenic model is one of monocyte nonresponsiveness to locally produced MCP-1 due to either receptor desensitization or neutralization of a chemoattractant gradient by high systemic concentrations of MCP-1. Regardless of the mechanism, the data indicate that constitutively high levels of MCP-1 expression do not induce monocytic infiltrates, and that MCP-1 is involved in the host response to intracellular pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant.
Carr, M. W., Roth, S. J., Luther, E., Rose, S. S., & Springer, T. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3652 · Cited by 1,198
Lira, S. A., Zalamea, P., Heinrich, J. N., Fuentes, M. E., Carrasco, D., Lewin, A. C., Barton, D. S., Durham, S., & Bravo, R. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.6.2039 · Cited by 115
Cited by
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Flynn, J. L., & Chan, J. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.93 · Cited by 2,155
Rollins, B. J. (1997) · Blood · doi:10.1182/blood.v90.3.909 · Cited by 1,984
Self-citationCytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Tedgui, A., & Mallat, Z. (2006) · Physiological Reviews · doi:10.1152/physrev.00024.2005 · Cited by 1,701
Monocyte-Mediated Defense Against Microbial Pathogens
Serbina, N. V., Jia, T., Hohl, T. M., & Pamer, E. G. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090326 · Cited by 1,123
Lu, B., Rutledge, B. J., Gu, L., Fiorillo, J., Lukacs, N. W., Kunkel, S. L., North, R., Gerard, C., & Rollins, B. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.601 · Cited by 1,017
Self-citationVerreck, F. A. W., de Boer, T., Langenberg, D. M. L., Hoeve, M. A., Kramer, M., Vaisberg, E., Kastelein, R., Kolk, A., de Waal-Malefyt, R., & Ottenhoff, T. H. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400983101 · Cited by 977
Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1
Gu, L., Tseng, S., Horner, R. M., Tam, C., Loda, M., & Rollins, B. J. (2000) · Nature · doi:10.1038/35006097 · Cited by 832
Self-citationChemokines as regulators of T cell differentiation
Luther, S. A., & Cyster, J. G. (2001) · Nature Immunology · doi:10.1038/84205 · Cited by 736
Defects in Macrophage Recruitment and Host Defense in Mice Lacking the CCR2 Chemokine Receptor
Kurihara, T., Warr, G., Loy, J., & Bravo, R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.10.1757 · Cited by 717
Hanschmann, E.-M., Godoy, J. R., Berndt, C., Hudemann, C., & Lillig, C. H. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4599 · Cited by 677
The immunological life cycle of tuberculosis
Ernst, J. D. (2012) · Nature Reviews Immunology · doi:10.1038/nri3259 · Cited by 577
Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice
Yin, F., Banerjee, R., Thomas, B., Zhou, P., Qian, L., Jia, T., Ma, X., Ma, Y., Iadecola, C., Beal, M. F., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091568 · Cited by 480
“This result is consistent with the report that overexpression of MCP-1 in transgenic mice disturbed the chemokine gradient and prevented timely monocyte infiltration into infected sites (Rutledge et al., 1995).”
ResultMonocyte Chemoattractant Protein-1 Accelerates Atherosclerosis in Apolipoprotein E-Deficient Mice
Aiello, R. J., Bourassa, P.-A. K., Lindsey, S., Weng, W., Natoli, E., Rollins, B. J., & Milos, P. M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.6.1518 · Cited by 466
Self-citationMahad, D. J., & Ransohoff, R. M. (2003) · Seminars in Immunology · doi:10.1016/s1044-5323(02)00125-2 · Cited by 415
Mukaida, N., Harada, A., & Matsushima, K. (1998) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(97)00022-1 · Cited by 401
Cellular and Molecular Dynamics in the Foreign Body Reaction
Luttikhuizen, D. T., Harmsen, M. C., & Luyn, M. J. A. V. (2006) · Tissue Engineering · doi:10.1089/ten.2006.12.1955 · Cited by 396
Rollins, B. J. (1996) · Molecular Medicine Today · doi:10.1016/1357-4310(96)88772-7 · Cited by 393
Self-citationNew Insights into the Biology of the Acute Phase Response
Suffredini, A. F., Fantuzzi, G., Badolato, R., Oppenheim, J. J., & O'Grady, N. P. (1999) · Journal of Clinical Immunology · doi:10.1023/a:1020563913045 · Cited by 391
The MCP/eotaxin subfamily of CC chemokines
Van Coillie, E., Van Damme, J., & Opdenakker, G. (1999) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(99)00005-2 · Cited by 350
Bertini, R., Zack Howard, O. M., Dong, H.-F., Oppenheim, J. J., Bizzarri, C., Sergi, R., Caselli, G., Pagliei, S., Romines, B., Wilshire, J. A., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.11.1783 · Cited by 337
Cavaillon, J.-M., Adib-conquy, M., Fitting, C., Adrie, C., & Payen, D. (2003) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540310015935 · Cited by 336
Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis
Peters, W., Scott, H. M., Chambers, H. F., Flynn, J. L., Charo, I. F., & Ernst, J. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.131207398 · Cited by 331
Chemokines in asthma: Cooperative interaction between chemokines and IL-13
Rosenwasser, L. J., Zimmermann, N., Hershey, G. K., Foster, P. S., & Rothenberg, M. E. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.139 · Cited by 331
Monocyte Chemoattractant Protein-1
Gu, L., Tseng, S. C., & Rollins, B. J. (1999) · Chemical Immunology and Allergy · doi:10.1159/000058723 · Cited by 326
Self-citationCCL2 (monocyte chemoattractant protein-1) and cancer
Conti, I., & Rollins, B. J. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.10.009 · Cited by 314
Self-citationKershaw, M. H., Wang, G., Westwood, J. A., Pachynski, R. K., Tiffany, H. L., Marincola, F. M., Wang, E., Young, H. A., Murphy, P. M., & Hwu, P. (2002) · Human Gene Therapy · doi:10.1089/10430340260355374 · Cited by 297
The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally?
Yoshimura, T. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.135 · Cited by 266
(2000) · Tuberculosis · doi:10.1201/9780824745301-19 · Cited by 265
Metadata
- Authors
- Rutledge, B. J., Rayburn, H., Rosenberg, R., North, R. J., Gladue, R. P., Corless, C. L., & Rollins, B. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1995-11
- Volume
- 155
- Issue
- 10
- Pages
- 4838-4843
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1583232767
- Cited by
- 189
- References
- 2
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.